Simoctocog Alfa
Simoctocog alfa is a recombinant B-domain deleted human coagulation factor VIII produced in human embryonic kidney cells, used for the prevention and treatment of bleeding episodes in patients with hemophilia A. As a B-domain deleted factor VIII, it retains full procoagulant activity while offering manufacturing advantages including human cell line production that may reduce immunogenicity. It is administered intravenously for on-demand bleeding treatment and prophylaxis.
Mekanisme Kerja
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Simoctocog alfa is a recombinant B-domain deleted human coagulation factor VIII produced in human embryonic kidney cells, used for the prevention and treatment of bleeding episodes in patients with hemophilia A. As a B-domain deleted factor VIII, it retains full procoagulant activity while offering manufacturing advantages including human cell line production that may reduce immunogenicity. It is administered intravenously for on-demand bleeding treatment and prophylaxis.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Simoctocog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108319. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="simoctocog-alfa"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/simoctocog-alfa/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/simoctocog-alfa/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/simoctocog-alfa/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="simoctocog-alfa"></drugfyi-drug>